ImmuCell Corporation Common Stock (ICCC)
Stock · NASDAQ · Health Care
$10.75as of 10/16/2026
Price chart
Active signals
ICCC Signal Track Record
How signals performed across all stocks →What ICCC's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 40 | +0.3% | 50% | September 16, 2026 |
| Bollinger Band Breakout | 23 | -4.4% | 35% | July 1, 2026 |
| Bollinger Band Breakdown | 15 | +9.4% | 60% | September 15, 2026 |
| 200-Day Moving Average TouchActive now | 13 | +3.2% | 69% | January 29, 2026 |
| Any 20-session window (baseline) | -0.6% | 46% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ICCC
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield Fi…
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Employees
- 73
- Website
- immucell.com/
Fundamentals
- 1-day range
- $10.15$10.8
- Market cap
- $99.70M
- P/E (trailing)
- 121.11
- P/E (forward)
- -98.09
- EPS (trailing)
- $0.08
- Dividend yield
- —
- Beta
- 0.60
- Avg. volume
- 20.8K
How ImmuCell Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 30, 2026 · via SEC EDGAR / Finnhub
ImmuCell Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- ICCCImmuCell Corporation Common Stock$10.75▲ 1.80%Market cap $99.70MP/E 121.11$4.52$12.1
- IMDXInsight Molecular Diagnostics Inc. Common Stock$3.01▼ 1.63%Market cap $154.99MP/E —$2.42$8.51
- QCLSQ/C Technologies Inc. Common Stock$0.538▼ 3.58%Market cap $21.99MP/E —$0.4201$8.17
- VNRXVolitionRX Limited Common Stock$0.18▼ 5.26%Market cap $9.23MP/E —$0.18$10.31
- TRIBTrinity Biotech plc American Depositary Shares$8.03▲ 1.26%Market cap $7.86MP/E —$5.01$52.5
- BMRABiomerica Inc. Common Stock$1.85▼ 1.60%Market cap $4.94MP/E —$1.45$3.21
- CDIOCardio Diagnostics Holdings Inc. Common stock$1.69▼ 3.98%Market cap $4.91MP/E —$0.97$7.91
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ICCC ImmuCell Corporation Common Stock | $99.70M | 121.11 | $10.75 | ▲ 1.80% | $4.52$12.1 |
| IMDX Insight Molecular Diagnostics Inc. Common Stock | $154.99M | — | $3.01 | ▼ 1.63% | $2.42$8.51 |
| QCLS Q/C Technologies Inc. Common Stock | $21.99M | — | $0.538 | ▼ 3.58% | $0.4201$8.17 |
| VNRX VolitionRX Limited Common Stock | $9.23M | — | $0.18 | ▼ 5.26% | $0.18$10.31 |
| TRIB Trinity Biotech plc American Depositary Shares | $7.86M | — | $8.03 | ▲ 1.26% | $5.01$52.5 |
| BMRA Biomerica Inc. Common Stock | $4.94M | — | $1.85 | ▼ 1.60% | $1.45$3.21 |
| CDIO Cardio Diagnostics Holdings Inc. Common stock | $4.91M | — | $1.69 | ▼ 3.98% | $0.97$7.91 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Boekhorst Paul Francis Olivier te · June 18, 2026 · Buy8.0K @ $9.5
- Wainman Paul R · April 15, 2026 · Grant11.9K
- David Scott Tomsche · April 15, 2026 · Grant11.9K
- Gloria F. Basse · April 15, 2026 · Grant11.9K
- Turner Kathy V · April 15, 2026 · Grant17.9K
Institutional Ownership
March 31, 2026
- Total shares held
- 1.33M
- Total value held
- $8.40M
- Institutional holders
- 26
- Unknown260.3K
- Unknown221.7K
- Unknown151.8K
- Unknown135.3K
- Unknown101.6K
- Unknown65.8K
- Unknown56.0K
- Unknown54.4K
- Unknown42.5K
- Unknown41.6K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
ICCC featured in research roundup alongside major tech and pharma names
ImmuCell Corporation was included in a recent Yahoo Finance article highlighting top research reports for Alphabet, Mastercard, and AbbVie. This mention places ICCC in the same discussion as large-cap companies, though the specific details of the research for ICCC are not provided in the summary. The stock currently trades within its 52-week range, with a trailing P/E of 115.1.
ICCC featured in research roundup alongside major tech and pharma names. ImmuCell Corporation was included in a recent Yahoo Finance article highlighting top research reports for Alphabet, Mastercard, and AbbVie. This mention places ICCC in the same discussion as large-cap companies, though the specific details of the research for ICCC are not provided in the summary. The stock currently trades within its 52-week range, with a trailing P/E of 115.1.